BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
Ischemia
,
Lung
,
DNA fingerprint
,
Phenobarbital
,
rs6983267
,
SIRT1
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
yl- 1
Summary
General Info
Curated Studies
Most Correlated Studies
L1000 CMAP - Breast cancer MCF7 cells treated with small molecule perturbagens (3 of 4)
L1000 CMAP - Breast cancer MCF7 cells treated with small molecule perturbagens (2 of 4)
L1000 CMAP - Breast cancer MCF7 cells treated with small molecule perturbagens (1 of 4)
L1000 CMAP - Hepatocellular carcinoma HEPG2 cells treated with small molecule perturbagens
L1000 CMAP - Breast adenocarcinoma SKBR3 cells treated with small molecule perturbagens
Explore Curated Studies Results
Literature
Most Relevant Literature
Recognition of the inherently unstable H2A nucleosome by Swc2 is a major determinant for unidirectio…
Regulation of Expression of Autophagy Genes by Atg8a-Interacting Partners Sequoia, YL-1, and Sir2 in…
Structural basis of H2A.Z recognition by SRCAP chromatin-remodeling subunit YL1.
Targeting VPS72 inhibits ACTL6A/MYC axis activity in HCC progression.
Identification cloning and functional analysis of novel natural antisense lncRNA CFL1-AS1 in cattle.
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
A Phase 1/2, Study of YL-15293 in Subjects With Advanced Solid Tumors With a KRAS G12C Mutation
A Phase 1, Study of YL-15293 in Subjects With Advanced Solid Tumors With a KRAS G12C Mutation
Study of AR-12 (2-Amino-N-[4-[5-(2 Phenanthrenyl)-3-(Trifluoromethyl)-1H-pyrazol-1-yl] Phenyl]-Aceta…
First in Human Dose Escalation Study of YL-13027 in Subjects With Advanced Stage Solid Tumors
A Phase 1b/2 Study of YL-13027 Combined With Sintilimab in Patients With Advanced Solid Tumors
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ